Consequently, the results demonstrated that the combination use of ribociclib plus everolimus plus exemestane offers significant safety and clinical advantages for patients with locally advanced or metastatic breast cancer (Study Details Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. This evidence concerns the gene ERBB2 and breast carcinoma.